leadf
logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals' explains the significance of latest WHO solidarity results

Faron Pharmaceuticals' (LON:FARN) Markku Jalkanen explains the context and meaning behind the latest results from a study that showed little impact from interferon Beta-1a injected under the skin in halting coronavirus-related deaths.

The World Health Organisation's (WHO) Solidarity trial compared 1412 patients who received IFN beta-1a and 2050 control subjects not receiving IFN beta-1a.

The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalised patients with COVID-19.

Quick facts: Faron Pharmaceuticals Ltd

Price: 275 GBX

AIM:FARN
Market: AIM
Market Cap: £128.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

on 18/9/20

2 min read